DIOVAN HCT Drug Patent Profile
✉ Email this page to a colleague
When do Diovan Hct patents expire, and when can generic versions of Diovan Hct launch?
Diovan Hct is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in DIOVAN HCT is hydrochlorothiazide; valsartan. There are thirty-two drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; valsartan profile page.
Summary for DIOVAN HCT
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 3 |
Clinical Trials: | 49 |
Patent Applications: | 219 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for DIOVAN HCT |
Drug Sales Revenues: | Drug sales revenues for DIOVAN HCT |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DIOVAN HCT |
What excipients (inactive ingredients) are in DIOVAN HCT? | DIOVAN HCT excipients list |
DailyMed Link: | DIOVAN HCT at DailyMed |
Recent Clinical Trials for DIOVAN HCT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
ARKAY Therapeutics | Phase 1/Phase 2 |
Albany Medical College | Phase 1/Phase 2 |
LanZhou University | N/A |
Pharmacology for DIOVAN HCT
Drug Class | Angiotensin 2 Receptor Blocker Thiazide Diuretic |
Mechanism of Action | Angiotensin 2 Receptor Antagonists |
Physiological Effect | Increased Diuresis |
Anatomical Therapeutic Chemical (ATC) Classes for DIOVAN HCT
Paragraph IV (Patent) Challenges for DIOVAN HCT
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
DIOVAN HCT | Tablets | hydrochlorothiazide; valsartan | 320 mg/12.5 mg and 320 mg/25 mg | 020818 | 1 | 2007-02-07 |
DIOVAN HCT | Tablets | hydrochlorothiazide; valsartan | 80 mg/12.5 mg 160 mg/12.5 mg 160 mg/25 mg | 020818 | 1 | 2005-12-02 |
US Patents and Regulatory Information for DIOVAN HCT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | DIOVAN HCT | hydrochlorothiazide; valsartan | TABLET;ORAL | 020818-001 | Mar 6, 1998 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Novartis | DIOVAN HCT | hydrochlorothiazide; valsartan | TABLET;ORAL | 020818-003 | Jan 17, 2002 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Novartis | DIOVAN HCT | hydrochlorothiazide; valsartan | TABLET;ORAL | 020818-002 | Mar 6, 1998 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Novartis | DIOVAN HCT | hydrochlorothiazide; valsartan | TABLET;ORAL | 020818-004 | Apr 28, 2006 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DIOVAN HCT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | DIOVAN HCT | hydrochlorothiazide; valsartan | TABLET;ORAL | 020818-005 | Apr 28, 2006 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | DIOVAN HCT | hydrochlorothiazide; valsartan | TABLET;ORAL | 020818-003 | Jan 17, 2002 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | DIOVAN HCT | hydrochlorothiazide; valsartan | TABLET;ORAL | 020818-002 | Mar 6, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | DIOVAN HCT | hydrochlorothiazide; valsartan | TABLET;ORAL | 020818-002 | Mar 6, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DIOVAN HCT
See the table below for patents covering DIOVAN HCT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hungary | 219343 | PROCESS FOR PRODUCING ACYLATED ARYLALKYLAMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIIONS COMPRISING THEM | ⤷ Try a Trial |
Finland | 910747 | ⤷ Try a Trial | |
Denmark | 1767206 | ⤷ Try a Trial | |
Denmark | 0443983 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for DIOVAN HCT
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0454511 | SPC/GB99/008 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015 |
0443983 | 98C004 | Belgium | ⤷ Try a Trial | PRODUCT NAME: VALSARTAN HYDROCHLOROTHIAZIDUM; NATL. REGISTRATION NO/DATE: 206 IS 250 F 3 19980624; FIRST REGISTRATION: FR 344300.5 19970925 |
0443983 | 91676 | Luxembourg | ⤷ Try a Trial | 91676, EXPIRES: 20160212 |
0443983 | CA 2010 00014 | Denmark | ⤷ Try a Trial | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |